HK74494A - Pharmaceutically useful polymorphic modification of buspirone - Google Patents

Pharmaceutically useful polymorphic modification of buspirone Download PDF

Info

Publication number
HK74494A
HK74494A HK74494A HK74494A HK74494A HK 74494 A HK74494 A HK 74494A HK 74494 A HK74494 A HK 74494A HK 74494 A HK74494 A HK 74494A HK 74494 A HK74494 A HK 74494A
Authority
HK
Hong Kong
Prior art keywords
buspirone hydrochloride
buspirone
polymorph
solid
crystalline form
Prior art date
Application number
HK74494A
Other languages
English (en)
French (fr)
Inventor
C. Simms Jack
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22225222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK74494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HK74494A publication Critical patent/HK74494A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Body Structure For Vehicles (AREA)

Claims (8)

  1. Niedriger schmelzende, polymorphe, kristalline Form von Buspironhydrochlorid, gekennzeichnet durch einen Schmelzpunkt von etwa 188°C bis etwa 192°C.
  2. Verwendung des niedriger schmelzenden, polymorphen Buspironhydrochlorids gemäß Anspruch 1 zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Angst bei einem Patienten, der dieser Behandlung bedarf.
  3. Pharmazeutlsches Mittel, umfassend das niedriger schmelzende, polymorphe Buspironhydrochlorid gemäß Anspruch 1 und einen Träger.
  4. Verfahren zur Herstellung der niedriger schmelzenden, polymorphen, kristallinen Form von Buspironhydrochlorid gemaß Anspruch 1, wobei man
    a) die kristalline Struktur von festem Buspironhydrochlorid zerstört, das die höher schmelzende, polymorphe, kristalline Form oder ein Gemisch aus höher und niedriger schmelzender kristalliner Form von Buspironhydrochlorid enthält,
    und man
    b) eine Rekristallisation unter Gleichgewichtsbedingungen bei einer Temperatur von weniger als etwa 95°C erfolgen läßt.
  5. Verfahren nach Anspruch 4, worin die Zerstörung der kristallinen Struktur von festem Buspironhydrochlorid durch Auflösen in einem Flüssigmedium erfolgt und die niedriger schmelzende, polymorphe, kristalline Form aus dem Flüssigmedium abgetrennt wird.
  6. Verfahren nach Anspruch 5, worin festes Buspironhydrochlorid, welches die höher schmelzende, polymorphe, kristalline Form oder ein Gemisch aus höher und niedriger schmelzender kristalliner Form von Buspironhydrochlorid enthält, in einem Flüssigmedium bei einer Temperatur von weniger als etwa 95°C über eine Zeitspanne bewegt wird, die ausreicht, um zu gewährleisten, daß das feste Buspironhydrochlorid ausschließlich aus der niedriger schmelzenden, polymorphen Form besteht.
  7. Verfahren nach Anspruch 5 oder 6, worin das Flüssigmedium ausgewählt ist unter Acetonitril, Isopropanol und Methylethylketon.
  8. Verfahren nach Anspruch 6, worin das Flüssigmedium Isopropanol ist und die Temperatur 25°C - 60°C beträgt.
HK74494A 1987-08-28 1994-07-28 Pharmaceutically useful polymorphic modification of buspirone HK74494A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/090,984 US5015646A (en) 1987-08-28 1987-08-28 Pharmaceutically useful polymorphic modification of buspirone

Publications (1)

Publication Number Publication Date
HK74494A true HK74494A (en) 1994-08-05

Family

ID=22225222

Family Applications (1)

Application Number Title Priority Date Filing Date
HK74494A HK74494A (en) 1987-08-28 1994-07-28 Pharmaceutically useful polymorphic modification of buspirone

Country Status (22)

Country Link
US (1) US5015646A (de)
EP (1) EP0304941B1 (de)
JP (1) JP2716740B2 (de)
KR (1) KR970011297B1 (de)
AT (1) ATE101147T1 (de)
AU (1) AU618549B2 (de)
CY (1) CY1785A (de)
DE (1) DE3887598T2 (de)
DK (1) DK170821B1 (de)
ES (1) ES2061576T3 (de)
FI (1) FI883961L (de)
HK (1) HK74494A (de)
HU (1) HU201322B (de)
IE (1) IE63071B1 (de)
IL (1) IL87468A (de)
MY (1) MY104061A (de)
NO (1) NO883805D0 (de)
NZ (1) NZ225896A (de)
OA (1) OA08908A (de)
PT (1) PT88356B (de)
YU (1) YU46962B (de)
ZA (1) ZA886082B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
HU217129B (hu) * 1993-07-16 1999-11-29 EGIS Gyógyszergyár Rt. Eljárás nagy tisztaságú buspiron gyógyászati hatóanyag előállítására
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
SK287928B6 (sk) 1998-06-19 2012-04-03 Teijin Pharma Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US6465255B1 (en) * 1999-01-29 2002-10-15 The Regents Of The University Of California Method for identifying and probing phase transitions in materials
KR100433165B1 (ko) * 2000-10-10 2004-05-27 엔앤비텍 주식회사 가공란의 제조 방법, 상기 방법에 의하여 제조된 가공란,및 가공란을 제조하기 위한 장치
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
NZ551356A (en) 2004-05-11 2009-09-25 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20080015240A1 (en) * 2004-11-12 2008-01-17 Mitsuru Teramoto Acid Salt of Benzimidazole Derivative and Crystal Thereof
EP1790343A1 (de) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de) * 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
CN118702676B (zh) * 2024-07-09 2026-01-27 济南大学 一种盐酸丁螺环酮晶型ii的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4351939A (en) * 1980-10-16 1982-09-28 Mead Johnson & Company Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen

Also Published As

Publication number Publication date
PT88356B (pt) 1995-03-31
NO883805D0 (no) 1988-08-25
KR970011297B1 (ko) 1997-07-09
EP0304941A1 (de) 1989-03-01
IL87468A (en) 1992-12-01
CY1785A (en) 1995-10-20
FI883961A0 (fi) 1988-08-26
DK478788D0 (da) 1988-08-26
US5015646A (en) 1991-05-14
ES2061576T3 (es) 1994-12-16
YU161688A (en) 1990-10-31
PT88356A (pt) 1989-06-30
NZ225896A (en) 1991-04-26
IE882528L (en) 1989-02-28
OA08908A (en) 1989-10-31
IE63071B1 (en) 1995-03-22
HU201322B (en) 1990-10-28
DE3887598T2 (de) 1994-05-19
ATE101147T1 (de) 1994-02-15
MY104061A (en) 1993-11-30
DK170821B1 (da) 1996-01-29
DE3887598D1 (de) 1994-03-17
AU618549B2 (en) 1992-01-02
IL87468A0 (en) 1989-01-31
YU46962B (sh) 1994-09-09
ZA886082B (en) 1989-04-26
JPS6471816A (en) 1989-03-16
JP2716740B2 (ja) 1998-02-18
FI883961A7 (fi) 1989-03-01
KR890003740A (ko) 1989-04-17
DK478788A (da) 1989-03-01
EP0304941B1 (de) 1994-02-02
HUT47564A (en) 1989-03-28
FI883961L (fi) 1989-03-01
AU2107688A (en) 1989-03-02

Similar Documents

Publication Publication Date Title
CN113454087B (zh) 固体形式的fgfr抑制剂化合物及其制备方法
EP0304941B1 (de) Pharmazeutisch verwendbare polymorphe Modifikation von Buspiron
US20080182856A1 (en) Novel crystalline forms of aripiprazole
JP2013018789A (ja) ４−メチル−ｎ−［３−（４−メチル−イミダゾール−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの結晶形態
US5354760A (en) Crystalline Tiagabine monohydrate, its preparation and use
US4810789A (en) Process for buspirone hydrochloride polymorphic crystalline form conversion
US6706710B2 (en) Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
EP3656768A1 (de) Beraprost-314d-kristalle und methoden zu ihrer herstellung
CN113336741B (zh) 雷贝拉唑钠无水物晶型及其制备方法
US4851420A (en) 2,6-diamino-3-halobenzylpyridines and processes for their manufacture as well as their use in pharmaceuticals
US20040038985A1 (en) Crystal forms of 1- [6-chloro-5-(trifluoromethly) -2-pyridinyl] piperazine hydrochloride
CN105992769A (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
JP2004530725A (ja) フェニルエタノールアミンの結晶形、その製造、およびそれを含む医薬組成物
US20040097528A1 (en) Crystalline solid famciclovir forms I, II, III and preparation thereof
EP1783118B1 (de) Herstellung von Risperidon
EP0771798A1 (de) Neue polymorphe formen von lesopitron dichlorhydrat und seinen hydratisierten formen, verfahren zu deren herstellung und dieseventhaltende zsammensetzungen
HK1177455A (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base
HK1177456A (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form
HK1116783B (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20050826